Top

Published in:

01-12-2021 | Ulcerative Colitis | Original Article

Inflammatory Bowel Disease Does Not Impact Mortality but Increases Length of Hospitalization in Patients with Acute Myocardial Infarction

Authors: Preetika Sinh, James H. Tabibian, Prachi S. Biyani, Kathan Mehta, Emad Mansoor, Edward V. Loftus Jr., Maneesh Dave

Published in: Digestive Diseases and Sciences | Issue 12/2021

Abstract

Background and Aim

Inflammatory bowel diseases (IBD) have been associated with increased risk of cardiovascular events. We aimed to investigate the outcomes of myocardial infarction (MI) in patients with IBD.

Methods

We performed a cross-sectional study utilizing data from the Nationwide Inpatient Sample from the years 1998 to 2010. ICD-9-CM codes were used to identify patients with Crohn’s disease (CD) (555.X), ulcerative colitis (UC) (556.X), and acute MI (410.X). Outcomes in patients with MI with and without IBD were compared. Univariate analysis was performed. Multivariate logistic regression was used to determine the effect of UC and CD on in-hospital MI mortality after adjusting for confounders.

Results

A total of 2,629,161 MI, 3,607 UC and 3784 CD patients were analyzed. UC (odds ratio [OR], 1.12; 95% CI 0.98–1.29) and CD (OR 0.99; 95% CI 0.86–1.15) did not affect in-hospital mortality in patients with MI. There was no difference between in-hospital mortality in patients with MI with or without UC (7.75% vs. 7.05%; p = 0.25) or in patients with MI with or without CD (6.50% vs. 6.59%; p = 0.87). The length of stay (LOS) was higher in IBD patients and total charges were statistically higher in patients with UC as compared to non-IBD patients ($65,182 vs. $53,542; p < 0.001).

Conclusions

This study shows that IBD does not impact in-hospital mortality from MI. However, patients with MI with IBD have longer LOS. Patients with UC have higher total hospitalization charges than patients with MI without IBD. Further prospective studies are needed to assess the outcomes of MI in IBD patients.

Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–1517.CrossRef

Dave M, Papadakis KA, Faubion WA. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin N Am. 2014;43:405–424. https://doi.org/10.1016/j.gtc.2014.05.003.CrossRef

Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270:147–157. https://doi.org/10.1111/j.1365-2796.2010.02310.x.CrossRefPubMed

Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46:261–271. https://doi.org/10.1016/J.SEMARTHRIT.2016.05.014.CrossRefPubMed

Mercurio V, Lobasso A, Barbieri L, et al. Inflammatory, serological and vascular determinants of cardiovascular disease in systemic lupus erythematosus patients. Int J Mol Sci. 2019;20:2154. https://doi.org/10.3390/ijms20092154.CrossRefPubMedCentral

Santilli S, Kast DR, Grozdev I, et al. Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center. J Transl Med. 2016;14:217. https://doi.org/10.1186/s12967-016-0947-0.CrossRefPubMedPubMedCentral

Aniwan S, Pardi DS, Tremaine WJ, Loftus EV. Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16:e1. https://doi.org/10.1016/j.cgh.2018.04.031.CrossRef

Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death: a Danish nationwide cohort study. PLoS ONE. 2013;8:e56944. https://doi.org/10.1371/journal.pone.0056944.CrossRefPubMedPubMedCentral

Panhwar MS, Mansoor E, Al-Kindi SG, et al. Risk of myocardial infarction in inflammatory bowel disease: a population-based national study. Inflamm Bowel Dis. 2018;25:1080–1087.CrossRef

10.

Singh S, Singh H, Loftus EV, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:382–393.e1. https://doi.org/10.1016/J.CGH.2013.08.023.CrossRefPubMed

11.

Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008;6:41–45. https://doi.org/10.1016/j.cgh.2007.09.016.CrossRefPubMed

12.

Kappelman MD, Horvath-Puho E, Sandler RS, et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937–943. https://doi.org/10.1136/gut.2010.228585.CrossRefPubMed

13.

Kirchgesner J, Beaugerie L, Carrat F, Andersen NN, Jess T, Schwarzinger M. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut. 2018;67:1261–1268. https://doi.org/10.1136/gutjnl-2017-314015.CrossRefPubMed

14.

Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2018;24:916–923. https://doi.org/10.1093/ibd/izx089.CrossRefPubMed

15.

Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62:689–694. https://doi.org/10.1136/gutjnl-2012-303285.CrossRefPubMed

16.

Tsai M-S, Lin C-L, Chen H-P, Lee P-H, Sung F-C, Kao C-H. Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. Inflamm Bowel Dis. 2014;20:502–507.CrossRef

17.

Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741–747. https://doi.org/10.1038/ajg.2011.63.CrossRefPubMed

18.

Hansson GK. Inflammation and atherosclerosis. Circulation. 2017;136:1875–1877. https://doi.org/10.1161/CIRCULATIONAHA.117.030484.CrossRefPubMed

19.

Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126. https://doi.org/10.1056/NEJM199901143400207.CrossRefPubMed

20.

Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663. https://doi.org/10.1016/S0140-6736(09)61963-2.CrossRefPubMed

21.

Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–2051. https://doi.org/10.1161/ATVBAHA.108.179705.CrossRefPubMedPubMedCentral

22.

Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17–28. https://doi.org/10.1136/annrheumdis-2016-209775.CrossRefPubMed

23.

Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–1697. https://doi.org/10.1002/art.24092.CrossRefPubMed

24.

Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007;102:662–667. https://doi.org/10.1111/j.1572-0241.2006.01018.x.CrossRefPubMed

25.

Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel J-F. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohn’s Colitis. 2014;8:469–479. https://doi.org/10.1016/j.crohns.2013.09.021.CrossRef

26.

Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Prognosis after first-time myocardial infarction in patients with inflammatory bowel disease according to disease activity: nationwide cohort study. Circ Cardiovasc Qual Outcomes. 2014;7:857–862. https://doi.org/10.1161/CIRCOUTCOMES.114.000918.CrossRefPubMed

27.

Steiner C, Elixhauser A, Schnaier J. The healthcare cost and utilization project: an overview. Eff Clin Pract. 2002;5:143–151.PubMed

28.

Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.CrossRef

29.

Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–210. https://doi.org/10.1136/gut.2007.128231.CrossRefPubMed

30.

Pemmasani G, Elgendy I, Mamas MA, Leighton JA, Aronow WS, Tremaine WJ. Epidemiology and clinical outcomes of patients with inflammatory bowel disease presenting with acute coronary syndrome. Inflamm Bowel Dis. 2020. https://doi.org/10.1093/ibd/izaa237.CrossRef

31.

Yandrapalli S, Nabors C, Goyal A, Aronow WS, Frishman WH. Modifiable risk factors in young adults with first myocardial infarction. J Am Coll Cardiol. 2019;73:573–584. https://doi.org/10.1016/j.jacc.2018.10.084.CrossRefPubMed

32.

Mehta K, Jaiswal P, Briggs F, et al. In-patient outcomes of hematopoietic stem cell transplantation in patients with immune mediated inflammatory diseases: a nationwide study. Sci Rep. 2018;8:6825. https://doi.org/10.1038/s41598-018-24060-4.CrossRefPubMedPubMedCentral

33.

Barnes EL, Beery RM, Schulman AR, McCarthy EP, Korzenik JR, Winter RW. Hospitalizations for acute myocardial infarction are decreased among patients with inflammatory bowel disease using a nationwide inpatient database. Inflamm Bowel Dis. 2016;22:2229–2237. https://doi.org/10.1097/MIB.0000000000000899.CrossRefPubMed

34.

Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009;104:1445–1451. https://doi.org/10.1038/ajg.2009.81.CrossRefPubMed

35.

Fumery M, Singh AG, Khera R, et al. Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology. 2017;152:S77. https://doi.org/10.1016/S0016-5085(17)30607-8.CrossRef

36.

Sridhar ARM, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohn’s Colitis. 2011;5:287–294. https://doi.org/10.1016/j.crohns.2011.01.011.CrossRef

37.

Ehrenpreis ED, Zhou Y, Alexoff A, Melitas C. Effect of the diagnosis of inflammatory bowel disease on risk-adjusted mortality in hospitalized patients with acute myocardial infarction, congestive heart failure and pneumonia. PLoS ONE. 2016;11:e0158926. https://doi.org/10.1371/journal.pone.0158926.CrossRefPubMedPubMedCentral

38.

de Graaf MA, Jager KJ, Zoccali C, Dekker FW. Matching, an appealing method to avoid confounding? Nephron Clin Pract. 2011;118:c315–c318. https://doi.org/10.1159/000323136.CrossRefPubMed

39.

Elbadawi A, Elgendy IY, Ha LD, et al. National trends and outcomes of percutaneous coronary intervention in patients ≥70 years of age with acute coronary syndrome (from the National Inpatient Sample Database). Am J Cardiol. 2019;123:25–32. https://doi.org/10.1016/j.amjcard.2018.09.030.CrossRefPubMed

40.

Le Gall G, Kirchgesner J, Bejaoui M, et al. Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. PLoS ONE. 2018;13:e0201991. https://doi.org/10.1371/journal.pone.0201991.CrossRefPubMedPubMedCentral

41.

Sinh P, Cross R. Cardiovascular risk assessment and impact of medications on cardiovascular disease in inflammatory bowel disease. Inflamm Bowel Dis. 2020. https://doi.org/10.1093/ibd/izaa258.CrossRef

42.

Weissman S, Sinh P, Mehta TI, et al. Atherosclerotic cardiovascular disease in inflammatory bowel disease: the role of chronic inflammation. World J Gastrointest Pathophysiol. 2020;11:104–113. https://doi.org/10.4291/wjgp.v11.i5.104.CrossRefPubMedPubMedCentral

43.

Kobo O, Mohamed MO, Farmer AD, et al. Outcomes of percutaneous coronary intervention in patients with Crohn’s disease and ulcerative colitis (from a Nationwide Cohort). Am J Cardiol. 2020;130:30–36. https://doi.org/10.1016/j.amjcard.2020.06.013.CrossRefPubMed

Title: Inflammatory Bowel Disease Does Not Impact Mortality but Increases Length of Hospitalization in Patients with Acute Myocardial Infarction
Authors: Preetika Sinh
James H. Tabibian
Prachi S. Biyani
Kathan Mehta
Emad Mansoor
Edward V. Loftus Jr.
Maneesh Dave
Publication date: 01-12-2021
Publisher: Springer US
Keywords: Ulcerative Colitis
Crohn's Disease
Chronic Inflammatory Bowel Disease
Myocardial Infarction
Published in: Digestive Diseases and Sciences / Issue 12/2021
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-020-06818-x

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Inflammatory Bowel Disease Does Not Impact Mortality but Increases Length of Hospitalization in Patients with Acute Myocardial Infarction

Abstract

Background and Aim

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background and Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2021

7,8-Dihydroxyflavone Enhanced Colonic Cholinergic Contraction and Relieved Loperamide-Induced Constipation in Rats

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Lidocaine Inhibits Hepatocellular Carcinoma Development by Modulating circ_ITCH/miR-421/CPEB3 Axis

DRG1 Maintains Intestinal Epithelial Cell Junctions and Barrier Function by Regulating RAC1 Activity in Necrotizing Enterocolitis

Prevalence of Clostridioides difficile and Other Gastrointestinal Pathogens in Patients with COVID-19

Perception of Illness and Its Association with Treatment Willingness in Patients with Newly Diagnosed Nonalcoholic Fatty Liver Disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page